PDF下载 ( 118 KB)
Study on the response to combined α-IFN, ribavilin and thymosin α1 for different types HCV infection and HCV-HBV coinfection
-
摘要: 为探讨不同基因型HCV及HCV、HBV重叠感染者对α -干扰素联合利巴韦林及胸腺肽治疗的反应 ,对171例接受干扰素联合利巴韦林治疗的HCV感染及HCV、HBV重叠感染者进行基因型调查 ,并分析对Ⅱ /1b型HCV感染的疗效。结果发现 ,Ⅳ /2b型HCV感染对干扰素联合利巴韦林治疗的应答率最高 （5 7 78% ） ,Ⅱ /1b型应答率最低 （11 76 % ）。联合胸腺肽治疗的Ⅱ /1b型患者应答率高于干扰素联合利巴韦林治疗组 （P <0 0 5 ） ;Ⅱ /1b型HCV无论单独感染还是与HBV重叠感染均表现出更低的应答率。干扰素、利巴韦林联合胸腺肽治疗有助于提高Ⅱ /1b型患者的应答率Abstract: To Study on the response to combined α-IFN, ribavilin and thymosin α 1 for different types HCV infection and HCV-HBV coinfection. Genotypes of HCV in 171 patients with HCV infection and HCV-HBV coinfection were investigated and the patients were treated with IFN+ribavilin, curative effect of IFN+ribavilin to different type HCV infection, HCV-HBV coinfection and the response of HCV-Ⅱ/1b to IFN+ribavilin+Thymosin αl theapy were analyzed. The response rates in the four types HCV infection were different, HCV-Ⅳ/2b was the highest (57.78%) , HCV-Ⅱ/1b was the lowest (11.76%) . The response rate in those patients with HCV-Ⅱ/1b infection who treated with Thymosin αl was 46.15%, higher than those without Thymosinαl group, P<0.05;and the complete response rate was 30.76%, showed significant difference compared with the latter. In patients with HCV-HBV coinfection, the response rate to IFN+ribavilin was 11.11%, HCV Ⅱ/1b displayed the lowest response than other types when it infection alone, and presented more lower response when coinfected with HBV. The response rate could be raised if Thymosinα 1 were added.
-
Key words:
- interferon /
- ribavilin /
- genotype /
- thymosin α 1 /
- HCV /
- HBV
-
[1]Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-Ⅰ interferon receptor gene expression in the liver[J].J Med Virol, 2001, 63 (3) ∶220-7. [2]Wawrzynowicz-syczewska M, Underhill JA, Clare MA, et al. HLA class Ⅱ genotypes associated with chronic hepatitis virus infection and response to α-interferon treatment in Poland[J]. Liver, 2000, 20∶234-239. [3]Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy[J].Hepatology, 1997, 25 (3) ∶769-71. [4]Mutchnick MG, Ehrinpreis MN, Kinzie JL, et al. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents[J].Antiviral Res, 1994, 24 (2-3) ∶245-57. [5]BonkovskyHL .TherapyofHepatitisC :Otheroptions[J].Hepatology, 1997, 26∶143s -
本文二维码
计量
- 文章访问数: 2126
- HTML全文浏览量: 17
- PDF下载量: 725
- 被引次数: 0
下载:
